Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSM Pharmaceutical Products business unit DSM Biologics has signed a contract with US based biotechnology company NKT Therapeutics to develop therapeutics based on natural killer T (NKT) cells.
Subscribe to our email newsletter
DSM Biologics provides and develops technologies relevant for optimized mammalian cell culture processes.
The contract covers the process development and cGMP manufacturing by DSM of their lead product iNKT mAb.
Upon exposure to microbial and viral pathogens NKT cells secrete high levels of specific cytokines which stimulate the immune system to eliminate pathogens.
DSM Biologics president Karen King said with a range of mammalian bioreactor sizes from 50 liters up to 1000 liters and, process and analytical development capabilities, DSM offers development and production flexibility combined with economy.
NKT Therapeutics chief scientific officer Alem Truneh said manipulation of NKT cells is an exciting new therapeutic strategy.